IRIS
MELILLO, ROSA MARINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.152
NA - Nord America 4.626
EU - Europa 4.163
SA - Sud America 719
AF - Africa 142
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 3
Totale 14.810
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.441
SG - Singapore 2.346
RU - Federazione Russa 1.555
IT - Italia 1.069
CN - Cina 940
VN - Vietnam 938
BR - Brasile 590
HK - Hong Kong 442
DE - Germania 300
UA - Ucraina 267
FR - Francia 190
FI - Finlandia 170
IE - Irlanda 137
IN - India 119
CA - Canada 118
NL - Olanda 112
SE - Svezia 110
GB - Regno Unito 109
JP - Giappone 72
AR - Argentina 48
BD - Bangladesh 45
MX - Messico 41
CI - Costa d'Avorio 37
ZA - Sudafrica 37
KR - Corea 36
PL - Polonia 30
IQ - Iraq 29
EC - Ecuador 24
ES - Italia 24
PH - Filippine 24
TH - Thailandia 22
ID - Indonesia 21
AT - Austria 18
PK - Pakistan 17
CO - Colombia 14
TR - Turchia 14
VE - Venezuela 14
MA - Marocco 13
UZ - Uzbekistan 12
KE - Kenya 11
CZ - Repubblica Ceca 10
CL - Cile 9
PY - Paraguay 9
EG - Egitto 8
JO - Giordania 8
TW - Taiwan 8
BE - Belgio 7
LT - Lituania 7
AE - Emirati Arabi Uniti 6
BG - Bulgaria 6
DZ - Algeria 6
NP - Nepal 6
SA - Arabia Saudita 6
CH - Svizzera 5
PE - Perù 5
AL - Albania 4
AU - Australia 4
AZ - Azerbaigian 4
BA - Bosnia-Erzegovina 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
HN - Honduras 4
HR - Croazia 4
IL - Israele 4
JM - Giamaica 4
KZ - Kazakistan 4
NG - Nigeria 4
RO - Romania 4
SN - Senegal 4
TN - Tunisia 4
UY - Uruguay 4
BY - Bielorussia 3
CR - Costa Rica 3
GE - Georgia 3
IR - Iran 3
KW - Kuwait 3
LK - Sri Lanka 3
MD - Moldavia 3
MY - Malesia 3
NI - Nicaragua 3
OM - Oman 3
SK - Slovacchia (Repubblica Slovacca) 3
AO - Angola 2
BH - Bahrain 2
HU - Ungheria 2
IS - Islanda 2
KH - Cambogia 2
LU - Lussemburgo 2
LY - Libia 2
NO - Norvegia 2
PA - Panama 2
SO - Somalia 2
SY - Repubblica araba siriana 2
TJ - Tagikistan 2
XK - ???statistics.table.value.countryCode.XK??? 2
ZM - Zambia 2
AD - Andorra 1
AG - Antigua e Barbuda 1
BB - Barbados 1
BJ - Benin 1
Totale 14.791
Salva come PNG Salva come JPEG
Città #
Singapore 1.034
San Jose 663
Hong Kong 426
Chandler 385
Moscow 383
Ashburn 333
Beijing 294
Jacksonville 271
Ho Chi Minh City 259
Santa Clara 207
Hanoi 204
Naples 156
Lauterbourg 132
Los Angeles 132
Princeton 132
Millbury 122
The Dalles 122
Nanjing 101
Napoli 95
Boston 94
Amsterdam 88
Buffalo 79
Hefei 73
Munich 69
New York 64
São Paulo 61
Tokyo 61
Dallas 58
Wilmington 55
Ann Arbor 54
Ottawa 49
Haiphong 44
Orem 41
Da Nang 40
Rome 35
Montreal 34
Nanchang 32
Redondo Beach 30
Denver 25
London 25
Tianjin 24
Warsaw 24
Chennai 23
Chicago 23
Hebei 23
Marigliano 23
Biên Hòa 22
Kronberg 22
Turku 22
Brooklyn 21
Des Moines 21
Poplar 21
Seattle 21
Atlanta 19
Milan 19
Boardman 18
Nuremberg 18
Rio de Janeiro 18
Council Bluffs 17
Frankfurt am Main 17
Johannesburg 17
Norwalk 17
Shenyang 17
Houston 16
Stockholm 16
Thái Nguyên 16
Falls Church 15
Salerno 15
Helsinki 14
Krefeld 14
Mexico City 14
Porto Alegre 14
Woodbridge 14
Changsha 13
Kochi 13
Augusta 12
Belo Horizonte 12
Cagliari 12
Dong Ket 12
Hangzhou 12
Phoenix 12
Seoul 12
Bacoli 11
Barano d'Ischia 11
Manchester 11
Mumbai 11
Shanghai 11
Bangkok 10
Brasília 10
Can Tho 10
Charlotte 10
Guayaquil 10
Hải Dương 10
Pune 10
San Francisco 10
Tashkent 10
Bari 9
Curitiba 9
Goiânia 9
Jiaxing 9
Totale 7.468
Salva come PNG Salva come JPEG
Nome #
Basi molecolari dell’effetto pro-tumorigenico dele chemochine nel cancro della tiroide. 577
The Impact of Resolution of Inflammation on Tumor Microenvironment: Exploring New Ways to Control Cancer Progression 194
PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2/Ras/MAPK signalling in thyroid cancer cells. 187
Peptide per rigenerare i tessuti lesionati. 183
HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity 179
Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. 169
Formyl Peptide Receptor 1 Suppresses Gastric Cancer Angiogenesis and Growth by Exploiting Inflammation Resolution Pathways 166
Probiotic Lactobacillus rhamnosus GG (LGG) restrains the angiogenic potential of colorectal carcinoma cells by activating a proresolving program via formyl peptide receptor 1 162
Therapeutic strategies to target the receptor tyrosine kinase AXL in thyroid cancer 155
Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. 152
Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway. 152
Mast cells have a protumorigenic role in human thyroid cancer. 148
Glucose Enhances Pro-Tumorigenic Functions of Mammary Adipose-Derived Mesenchymal Stromal/Stem Cells on Breast Cancer Cell Lines 147
Genetic Alterations in differentiated thyroid cancer:what can be expected for gene expression profiling of thyroid carcinomas 145
The Insulin Receptor Substrate (IRS)-1 recruits Phosphatidylinositol 3-Kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret. 142
Role of Formyl Peptide Receptors In Gastrointestinal Healing 142
AXL is an oncotarget in human colorectal cancer 140
Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer. 139
Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1 139
New perspectives in cancer: Modulation of lipid metabolism and inflammation resolution 136
The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma 135
Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease 135
Helicobacter pylori Hp(2-20) promotes migration and proliferation of gastric epithelial cells by interacting with formyl peptide receptors in vitro and accelerates gastric mucosal healing in vivo. 135
AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer 134
Molecular biology of the MEN2 gene 133
Suppression of ADP-ribosylation reversal triggers cell vulnerability to alkylating agents 132
The lncRNA RMST is drastically downregulated in anaplastic thyroid carcinomas where exerts a tumor suppressor activity impairing epithelial-mesenchymal transition and stemness 132
Thyroid cancer and inflammation. 131
The Formyl Peptide Receptor 1 Exerts a Tumor Suppressor Role in Human Gastric Cancer by Suppressing Angiogenesis 131
Il Sistema Immunitario 130
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). 129
The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. 129
The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis. 128
Inflammation in thyroid oncogenesis. 127
Toll‐like receptor 7 mediates inflammation resolution and inhibition of angiogenesis in non‐small cell lung cancer 127
Helicobacter pylori Hp(2-20) promotes gastric mucosal healing and interacts with formyl-peptide receptors 125
Formyl peptide receptors at the interface of inflammation, angiogenesis and tumor growth 125
Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. 121
RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase 120
Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer 120
Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene. 119
Receptor- and non-receptor tyrosine kinases induce processing of the amyloid precursor protein: role of the low-density lipoprotein receptor-related protein. 119
Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes. 118
Molecular mechanisms of RET activation in human cancer 118
PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. 117
IL-8, But Not The Related Chemokine CXCL1, Sustains An Autocrine Circuit Necessary For the Properties and Functions of Thyroid Cancer Stem Cells. 116
The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. 114
OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome. 112
RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho. 112
Overexpression of the Cytokine Osteopontin Identifies Aggressive Laryngeal Squamous Cell Carcinomas and Enhances Carcinoma Cell Proliferation and Invasiveness. 111
Cloning and characterization of H4 (D10S170), a gene involved in RET rearrangements in vivo. 111
Recent advances in understanding immune phenotypes of thyroid carcinomas: Prognostication and emerging therapies [version 1; referees: 2 approved] 111
Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins. 110
The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway. 109
RET ONCOGENE ACTIVATION IN HUMAN THYROID NEOPLASMS IS RESTRICTED TO THE PAPILLARY CANCER SUBTYPE 108
Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival 108
Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation. 108
A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. 105
In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies 105
Molecular heterogeneity of RET loss of function in Hirschsprung's disease 104
Roles of mast cells and their mediators in human thyroid carcinomas. 103
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) 103
BRAF is a therapeutic target in aggressive thyroid carcinoma. 102
L’osteopontina: un nuovo marcatore biologico dei carcinomi della testa e del collo 102
Tumor Suppressor Role of Formyl Peptide Receptor 1 in Human Gastric Cancer 100
Molecular heterogeneity of RET loss of function in Hirschsprung's disease. 98
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma 97
Signalling of the Ret receptor tyrosine kinase through the c-Jun N-terminal Protein Kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret 97
Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. 96
The docking protein FRS2 links RET and its oncogenic forms with the RAS/MAPK cascade. 95
Different mutations of the RET gene cause different human tumoral diseases. 94
The PTC oncogene is able to dedifferentiate a rat thyroid epithelial cell line in culture 92
Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma. 91
INCREASED IN-VIVO PHOSPHORILATION OF RET TYROSINE 1062 IS A POTENTIAL PATHOGENETIC MECHANISM OF MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B. 89
Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes 89
ROLES OF MAST CELLS AND THEIR MEDIATORS IN HUMAN THYROID CARCINOMAS 88
RET\PTC activation in human thyroid carcinomas 88
Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. 87
Mast cells play (a) protumorigenic roles in human thyroid cancer. 87
Activation of RET oncogene and thyroid carcinogenesis 87
Molecular mechanisms of RET activation in human cancer. 87
Ret-mediated mitogenesis requires Src kinase activity. 86
Molecular mechanisms of RET activation in human neoplasia 85
Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B. 85
Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. 84
Small-molecule inhibitors of chemokine receptors as novel anticancer therapy of human thyroid carcinomas. 84
Mast cells and basophils in angiogenesis: bridging the gap between inflammation and tumors 84
Tyrosines 1015 and 1062 are in vivo auto-phosphorylation site in Ret and Ret-derived oncoproteins 83
Functional role of the CXCR4 chemokine receptor in thyroid cancer. 83
Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase 83
A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure. 83
Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas 82
Molecular mechanisms of RET activation in human neoplasia. 82
Expression of the RET/PTC1 oncogene impairs the activity of TTF-1 and Pax-8 thyroid transcription factors. 82
Helicobacter pylori Hp(2-20) promotes gastric mucosal healing and interacts with formyl-peptide receptors. 82
RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. 81
Genetics: The genomic landscape of papillary thyroid carcinoma 80
Positive and negative regulation of cell proliferation by E2F-1: influence of protein level and human papillomavirus oncoproteins 79
Human N-ras, TRK-T1, and RET/PTC3 oncogenes, driven by a thyroglobulin promoter, differently affect the expression of differentiation markers and the proliferation of thyroid epithelial cells 79
Multiple anti-tumor effects of Reparixin on thyroid cancer 79
Totale 11.906
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.746
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.746
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021132 0 0 0 0 0 0 0 0 0 23 89 20
2021/2022742 22 3 4 9 13 24 19 21 149 32 151 295
2022/20231.026 155 64 14 102 101 120 12 99 193 89 54 23
2023/2024710 27 70 95 69 44 49 30 109 13 18 128 58
2024/20253.699 221 274 17 22 63 208 389 216 296 403 1.252 338
2025/20266.892 841 500 759 756 1.245 281 763 436 888 423 0 0
Totale 15.067